4.6 Article

Expansion, harvest and cryopreservation of human mesenchymal stem cells in a serum-free microcarrier process

期刊

BIOTECHNOLOGY AND BIOENGINEERING
卷 112, 期 8, 页码 1696-1707

出版社

WILEY
DOI: 10.1002/bit.25582

关键词

serum-free; human mesenchymal stem cell; microcarrier expansion; harvest; cryopreservation; regenerative medicine

资金

  1. Engineering and Physical Sciences Research Council (EPSRC)
  2. Biotechnology and Biological Sciences Research Council (BBSRC)
  3. FUJIFILM Diosynth Biotechnologies
  4. BBSRC [BB/I017062/1] Funding Source: UKRI
  5. Biotechnology and Biological Sciences Research Council [BB/I017062/1] Funding Source: researchfish

向作者/读者索取更多资源

Human mesenchymal stem cell (hMSC) therapies are currently progressing through clinical development, driving the need for consistent, and cost effective manufacturing processes to meet the lot-sizes required for commercial production. The use of animal-derived serum is common in hMSC culture but has many drawbacks such as limited supply, lot-to-lot variability, increased regulatory burden, possibility of pathogen transmission, and reduced scope for process optimization. These constraints may impact the development of a consistent large-scale process and therefore must be addressed. The aim of this work was therefore to run a pilot study in the systematic development of serum-free hMSC manufacturing process. Human bone-marrow derived hMSCs were expanded on fibronectin-coated, non-porous plastic microcarriers in 100mL stirred spinner flasks at a density of 3x10(5)cells.mL(-1) in serum-free medium. The hMSCs were successfully harvested by our recently-developed technique using animal-free enzymatic cell detachment accompanied by agitation followed by filtration to separate the hMSCs from microcarriers, with a post-harvest viability of 99.63 +/- 0.03%. The hMSCs were found to be in accordance with the ISCT characterization criteria and maintained hMSC outgrowth and colony-forming potential. The hMSCs were held in suspension post-harvest to simulate a typical pooling time for a scaled expansion process and cryopreserved in a serum-free vehicle solution using a controlled-rate freezing process. Post-thaw viability was 75.8 +/- 1.4% with a similar 3h attachment efficiency also observed, indicating successful hMSC recovery, and attachment. This approach therefore demonstrates that once an hMSC line and appropriate medium have been selected for production, multiple unit operations can be integrated to generate an animal component-free hMSC production process from expansion through to cryopreservation. Biotechnol. Bioeng. 2015;112: 1696-1707. (c) 2015 The Authors. Biotechnology and Bioengineering Published by Wiley Periodicals, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据